Ionis Pharmaceuticals, Inc. IONS

Company Overview

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of RNA-targeted therapeutics based on antisense oligonucleotide (ASO) technology. The company operates primarily within the biopharmaceutical and genetic medicine industries, developing drugs that selectively inhibit the production of disease-causing proteins at the RNA level. Ionis’s core business model combines internal drug development with strategic collaborations that generate licensing revenue, milestone payments, and royalties.

The company’s primary revenue drivers include partnered programs with large pharmaceutical companies, royalties from approved medicines, and milestone payments tied to clinical and regulatory progress. Ionis serves global markets, with a strong focus on rare genetic diseases, cardiometabolic disorders, neurological diseases, and select broader population conditions. Its strategic advantage lies in its proprietary antisense technology platform, long-standing expertise in RNA biology, and a diversified pipeline spanning early research through commercial-stage assets. Founded in 1989 as Isis Pharmaceuticals, the company rebranded as Ionis Pharmaceuticals in 2015 to better reflect its scientific focus and global identity.